Open an account

Brainsway

BWAY · TEL

$11.25−$0.19 (−1.66%)TodayMarket closed ·
Prev close $11.44

About BWAY

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees
129
Headquarters
Jerusalem
Listed
Dec 24, 2006
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
brainsway.com

BWAY key statistics

Market cap
1.46B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
105.91K
Volume
52.47K
Open price
$11.40
High today
$11.40
Low today
$11.09
52 Week high
$17.40
52 Week low
$7.14

Brainsway (BWAY) at a glance

Brainsway (BWAY) last traded at $11.25, with a market cap of 1.46B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.09 and $11.40. The current price is 1.4% above the day's low and 1.3% below its high.

Volume so far is 52.47K shares, below the average of 105.91K shares a day.

Over the past year Brainsway has ranged from $7.14 to $17.40, and now sits 40% of the way up that range.

Brainsway met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.207 per share against an estimate of $0.1516.

The average analyst price target is $0.1997, 98.2% below the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $0.1997
Low
$0.1978
Now
$11.25
High
$0.2056

BWAY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 52.2% on average.

  1. Q3 FY24: reported $0.074 per share against an estimate of $0.00
  2. Q4 FY24: reported $0.148 per share against an estimate of $0.0766
  3. Q1 FY25: reported $0.072 per share against an estimate of $0.0931
  4. Q2 FY25: reported $0.179 per share against an estimate of $0.0917
  5. Q3 FY25: reported $0.134 per share against an estimate of $0.0988
  6. Q4 FY25: reported $0.26 per share against an estimate of $0.1313
  7. Q1 FY26: reported $0.187 per share against an estimate of $0.1748
  8. Q2 FY26: reported $0.207 per share against an estimate of $0.1516

BWAY news

  • Press releaseGlobe Newswire

    BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

  • Press releaseGlobe Newswire

    BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

  • Press releaseGlobe Newswire

    BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

  • Press releaseGlobe Newswire

    BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

  • Press releaseGlobe Newswire

    BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

  • Press releaseGlobe Newswire

    BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026

  • Press releaseGlobe Newswire

    BrainsWay Announces Strategic Investment in Radial Health, Inc.

  • Press releaseGlobe Newswire

    BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral

Similar companies

Companies in the same industry as Brainsway

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.